+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Prognostic and Therapeutic Applications of RKIP in Cancer

  • ID: 4844406
  • Book
  • February 2020
  • Elsevier Science and Technology

Prognostic and Therapeutic Applications of RKIP in Cancer provides updated reviews on the chemistry, signaling, pre-clinical and clinical activities, and role of RKIP expression levels for diagnostics, prognosis and potential interventions. The development of novel compounds and conjugates that selectively induce RKIP expression in cancer open a novel era of new therapeutics and their potential in the treatment of highly resistant cancers and metastases. Edited and written by internationally renowned experts in the field of novel therapeutics for cancer, this book is a valuable source for cancer researchers, medical scientists, clinicians, clinical pharmacologists, and graduate students.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
1. RKIP: General Properties in Human MalignanciesInsight on the Role of RKIP in Cancer through Key Protein Partners and Cellular Protrusions Francoise Schoentgen 2. Function of BACH1 as a key target of RKIP in Breast Cancer Marsha Rich Rosner & Jiyoung Lee 3. Pleiotropic Activities of RKIP in Cancer: Role in Survival, EMT, Chemo-immuno-resistance, and Autophagy Yuhao Wang & Benjamin Bonavida 4. Role of RKIP in the Tumor Response to Photo-oxidative Damage Valentina Rapozzi & Luigi Emilio Xodo 5. A Review of RKIP Promotion of Tumour Progression, Metastasis and Poor Outcome in Multiple Solid Tumour Types Sharon Glynn, Eoin Dervan, & Dibyangana Bhattacharyya 6. Tumor hypoxic stress, cellular plasticity and RKIP Salem Chouaib, Stéphane Terry, Stéphanie Buart, & Abérémane Abdou 7. RKIP in Uterine Tissues Pasquapina Ciarmela 8. The Role of RAF Kinase Inhibitor Protein in Hematologic Malignancies Armin Zebisch 9. RKIP Regulation and Crosstalks Regulation of RKIP Expression in Breast Cancer Cells by miRNA Kam Yeung, Julius Castro, Hussain N. Odeh, Christopher Figy, Miranda L. Yeung, & Robert Trumbly 10. The Master Cellular Regulators "RKIP & GSK3ß?: Their Interactions and Repercussions on Cancer Mira Bosso & Fahd Al-Mulla 11. Identification of Regulatory Crosstalks between RKIP and BCRA1 Tumor Suppressors in Healthy Tissues and Cancer (Breast and Ovarian): Therapeutic Implications Martina Rama & Benjamin Bonavida 12. RKIP a Master of Regulatory Pathways: Perspectives Khosrow Kashfi, Yongxin Zhou, & Gabrielle M. Corrente 13. Local and Systemic Endothelial Dysfunction in Cancer: RKIP-Mimetic, Therapy of Cancer and Endothelium-Safety Marta Smeda, Marek Grosicki, & Stefan Chlopicki 14. Stochastic Modeling for Investigation of Regulation of Transcription of RKIP gene Alexandre Ramos, Leonardo dos Reis Gama, Mauro César Cafundó Morais, & Poliana Cristina de Melo Martins 15. Anti-cancer effect of RKIP via modulating autophagy during metastasis Deok Ryong Kim & Mahmoud Ahmed 16. RKIP and Inflammation The Role of Raf Kinase Inhibitory Protein in Inflammation Steve Shenouda, Fahd Al-Mulla, Mira Bosso,& Rasheed Ahmad 17. Role of RKIP in inflammatory responses Xiaojian Wang & Wenlong Lin 18. RKIP: Prognostic and Therapeutic Implications RKIP in Human Diseases and its Potential as a Prognostic Indicator and Therapeutic Target Apostolos Zaravinos & Theodoulakis Christofi 19. Therapeutic Targeting of SNAIL, RKIP and YY1 in Tumor Metastasis and Drug Resistance Nadire Özenver & Thomas Efferth 20. Implications of RKIP protein in cancer prognosis and therapy response: a literature update Diana Cardoso-Carneiro, Ana Raquel-Cunha, Joana Pinheiro, Maria Gabriela-Freitas, Patrícia Fontão, Rui M. Reis, & Olga Martinho 21. Theranostic Role of RKIP in Cancer Ganji Purnachandra Nagaraju, Begum Dariya, Gayathri Chalikonda, & Afroz Alam 22. Downregulation of the Raf Kinase Inhibitory Protein (RKIP) in Clear Cell Renal Cell Carcinoma Associates with Poor Prognosis Damu Tang Anil Kapoor, Xiaozeng Lin, David Rodrig
Note: Product cover images may vary from those shown
Benjamin Bonavida Professor, Department of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, USA.

Benjamin Bonavida, PhD, has been involved in the field of immunology and cancer biology for several decades and has published extensively in the fields of cancer resistance, chemotherapy, immunotherapy, and various molecular approaches to circumvent the resistance of the cancer cells using sensitizing agents. Accordingly, he was the first to publish a book on tumor sensitization in 2008. More recently, Dr. Bonavida is the Series Editor of 3 series published by Elsevier/Academic Press ("Cancer Sensitizing Agents for Chemotherapy,” "Breaking Cancer Resistance to Therapeutic Antibodies,” and "Breaking Tolerance to Anti-Cancer Immunotherapy”) and several books have been published and many are in development. He has published extensively in the field of NK biology and cytotoxicity in the past, and many of these publications were in collaboration with the co-editor Dr. Anahid Jewett.
Stavroula Baritaki Division of Surgical Oncology, School of Medicine, University of Crete, Heraklion, Crete, Greece.

Stavroula Baritaki's, PhD, areas of expertise mainly include the understanding of the molecular mechanisms involved in tumor cell therapeutic resistance and acquisition of a metastatic phenotype. Her studies have revealed novel gene products, including Raf-1 Kinase inhibitory protein (RKIP), as members of molecular 'circuitries and networks' that critically affect tumor immunosurveillance, resistance to chemo/immune-therapy and early metastasis-related cell transformations, such as EMT. Followed by further studies on the epigenetic and post-translational regulation of RKIP in many cancer types, her overall findings have firstly suggested the RKIP downregulation in cancer cells as a putative gene signature of tumor chemo/immune-resistance and EMT with prognostic and therapeutic significance in an individualized basis. On this context, Dr. Baritaki has extended her research interests in identifying novel agents that through RKIP induction are able to inhibit EMT or improve either the host immunosurveillance and/or the efficacy of anti-tumor therapies, especially if they are combined with conventional immuno-stimulatory or chemotherapeutic regimens. Most of these agents are currently under clinical trials.
Note: Product cover images may vary from those shown